Nanomix Corp. engages in the development of mobile point-of-care (POC) diagnostics, with a handheld testing platform and assays that provide rapid, accurate and quantitative information. The company is headquartered in Lawrence, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2012-02-29. The firm operates through its Nanomix eLab System platform and assays that provide quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The platform is designed to provide rapid test results in a handheld device at the first point of patient contact in locations that range from emergency departments to long term and assisted care facilities, to urgent care and emergency medical response settings. Its platform is performed in a range of in vitro diagnostic assays, such as electrochemical immunoassay and enzymatic assays. Its eLab System utilizes a nano-biosensor with multiple detection electrodes to generate multiple electrochemical assay results. Its S1 Assay panel is used as an aid in diagnosing infections, such as sepsis. Its CRP test results can be used to evaluate infection, tissue injury, and inflammatory disorders.

Industry: Pharmaceutical Preparations Peers: Abbott Laboratories Aethlon Medical Inc BRAIN SCIENTIFIC INC. INVO Fertility Inc Femasys Inc HeartSciences Inc Myomo Inc ENvue Medical Inc Valion Bio Inc